← Eichor
Condition: Metastatic Castration Resistant Prostate Cancer Patients Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Metastatic Castration Resistant Prostate Cancer Patients

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Study of Tinengotinib (TT-00420) in Combination With Standard Treatments in People With Prostate Cancer
Phase 1/Phase 2 · 12 location(s) · Memorial Sloan Kettering Cancer Center · NCT06457919Carboplatin or Olaparib for BRcA Deficient Prostate Cancer
Phase 2 · 18 location(s) · VA Office of Research and Development · NCT04038502Working Out M0 Bipolar Androgen Therapy
Phase 2 · 12 location(s) · Australian and New Zealand Urogenital and Prostate Cancer Tr · NCT06594926177Lu-P17-087/177Lu-P17-088 in Patients With Metastatic Castration-resistant Prostate Cancer
EARLY_Phase 1 · 1 location(s) · Peking Union Medical College Hospital · NCT05603559Treatment of Patients With Progressive mCRPC With 177Lu-PSMA-617
Phase 2 · 1 location(s) · Ebrahim S Delpassand · NCT06972628Phase 1 Study of ACE-232 to Treat Patients With Metastatic Castration-Resistant Prostate Cancer
Phase 1 · 8 location(s) · Acerand Therapeutics (Hong Kong) Limited · NCT06801236The Impact of Metastatic Directed Radiotherapy (MDRT) on Oligoprogressive Castration Resistant Prostate Cancer (CRPC)
Phase 2 · 2 location(s) · University Medical Center Groningen · NCT07038304A Study in Patients With Metastatic Castration-Resistant Prostate Cancer
Phase 1 · 10 location(s) · Flare Therapeutics Inc. · NCT07719361Kidney Function and Risk Factors in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Undergoing 177
Phase N/A · 1 location(s) · Hannah Schaefer · NCT06720532Pembrolizumab Plus 177Lu-PSMA-617 in Patients With Castration Resistant Prostate Cancer
Phase 2 · 1 location(s) · University of California, San Francisco · NCT05766371Observation Study to Evaluate the Efficacy and Safety of Ifosfamide/Mesna in Patients With Metastatic Castration-resista
Phase N/A · 1 location(s) · Yonsei University · NCT06236789A Phase III Study Comparing HRS-4357 With Novel Androgen Receptor Pathway Inhibitors in Patients With Progressive, PSMA-
Phase 3 · 1 location(s) · Jiangsu HengRui Medicine Co., Ltd. · NCT07311694A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of INV-9956 in Adult Patients
Phase 1/Phase 2 · 22 location(s) · Shenzhen Ionova Life Sciences Co., Ltd. · NCT06609005A Clinical Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of [225Ac]Ac-PSMA-XT Injection in Patient
Phase 1 · 1 location(s) · Xiaorong Sun · NCT07135102A Multicenter, Open-label, Non-randomized Phase I/IIa Clinical Trial to Evaluate INR102 Injection in Patients With Prost
Phase 1/Phase 2 · 2 location(s) · Yunhe Pharmaceutical (Tianjin) Co., Ltd · NCT06970119PRostate Olaparib Real World Evidence Study
Phase N/A · 65 location(s) · AstraZeneca · NCT060318053D1015 Injection for Patients With mCRPC
Phase 1 · 1 location(s) · Chunjing Yu · NCT07537010Study of HLD-0915 in Patients With Metastatic Prostate Cancer
Phase 1/Phase 2 · 12 location(s) · Janssen Research & Development, LLC · NCT06800313A Study to Investigate the Safety and Tolerability of Oral INR731 Single Agent or in Combination With Androgen Receptor
Phase 1 · 3 location(s) · Novartis Pharmaceuticals · NCT07570979Cabazitaxel +/- Carboplatin vs 177Lu-PSMA-617 in Metastatic Castrate-resistant Prostate Cancer
Phase 2 · 1 location(s) · Case Comprehensive Cancer Center · NCT06738303HER2 FPBMC in Patients With Metastatic Breast and Prostate Cancer (AM006)
Phase 1/Phase 2 · 1 location(s) · University of Virginia · NCT07441889Phase I Study of HSK46575 in Patients With Metastatic Castration-Resistant Prostate Cancer
Phase 1 · 1 location(s) · Haisco Pharmaceutical Group Co., Ltd. · NCT0700791064Cu-GRIP B in Patients With Advanced Malignancies
Phase 1/Phase 2 · 1 location(s) · Rahul Aggarwal · NCT05888532Phase II Randomised Controlled Trial of Patient-specific Adaptive vs. Continuous Abiraterone or eNZalutamide in mCRPC
Phase 2 · 19 location(s) · Leiden University Medical Center · NCT05393791Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Compared to C
Phase 3 · 174 location(s) · SWOG Cancer Research Network · NCT06470243Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer
Phase 2 · 1 location(s) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · NCT06059118Liquid Biopsy Under PSMA Radioligand Therapy
Phase N/A · 3 location(s) · Wuerzburg University Hospital · NCT07118436A Study of TRC003 in the Treatment of Patients With Progressive PSMA-positive mCRPC
Phase 1/Phase 2 · 2 location(s) · C Ray Therapeutics · NCT07567521A Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 In Participants With Advanced or Metastatic P
Phase 1 · 26 location(s) · Genentech, Inc. · NCT05800665Bipolar Androgen Therapy to Restore Sensitivity to Androgen Deprivation Therapy for Patients With Metastatic Castration
Phase 1 · 1 location(s) · Roswell Park Cancer Institute · NCT06305598
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.